Hst Global(OTC) HSTC

Market Cap$91.93M

Since IPO (2008)-100%

5 Year+550%

1 Year+324,900%

1 Month-7%

$0.65

+0.00%

+0.00Today

Hst Global last closing stock price
Metric	Price	Date
Last close	USD 0.65	2026-08-12

Hst Global stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.14%	USD 0.70	2026-07-23
1 month	-7.14%	USD 0.70	2026-07-07
3 month	+30%	USD 0.50	2026-05-12
Year to date	-34.34%	USD 0.99	2025-12-26
1 year	+324,900%	USD 0.00	2025-08-05
3 year	+116.67%	USD 0.30	2023-08-09
5 year	+550%	USD 0.10	2021-08-13
Since inception	-99.62%	USD 172.50	2008-05-12

Hst Global Financials at a Glance

Market Cap

$91.93M

Revenue (TTM)

$767.94K

Net Income (TTM)

-$442.68K

EPS (TTM)

-$0.00

P/E Ratio

-151.16

Dividend

$0.00

Beta (Volatility)

13.04 (High)

Dividend

$0.00

Beta (Volatility)

13.04 (High)

Price

$0.65

Volume

Open

$0.65

Price

$0.65

Volume

Open

$0.65

Previous Close

$0.65

Daily Range

$0.65 - $0.65

52-Week Range

$0.00 - $1.05

Estimated Earnings Date

Jul 6, 2026

Dividend

$0.00

Beta (Volatility)

13.04 (High)

Price

$0.65

Volume

Open

$0.65

Previous Close

$0.65

Daily Range

$0.65 - $0.65

52-Week Range

$0.00 - $1.05

Estimated Earnings Date

Jul 6, 2026

HSTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hst Global

HST Global, Inc. operates as a biotechnology firm dedicated to integrated health and wellness. The company establishes and acquires a global network of specialized wellness centers, offering homeopathic and alternative treatments primarily for patients suffering from advanced-stage cancers.

Products and Services

Specialized wellness centers for alternative cancer treatments
Development of homeopathic therapeutic candidates
Focus on late-stage cancer and critical condition therapies

Growth Outlook

Recent quarterly revenue increased to $206,059, up from $154,240
Gross profit margin improved to 80.5% in Q2 2026
Expansion plans for additional wellness centers globally

Financial Highlights

Trailing twelve months revenue of $1,000,000, indicating growth potential
Net income of $5,636 in Q2 2026, a positive shift from previous losses
Cash and cash equivalents increased to $20,618 in Q2 2026

HST Global, Inc. is positioned in the biotechnology sector, focusing on innovative health solutions. The recent increase in quarterly revenue and improvement in gross profit margin reflect a positive trend in operational efficiency. The company's commitment to developing alternative therapies for late-stage cancers aligns with growing market demand for holistic health solutions. With plans for expansion and a solid financial foundation, HST Global, Inc. presents an intriguing opportunity for potential investors interested in the biotechnology field.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Michael P. Fortkort

Website

www.hstglobal.com

Headquarters

Virginia Beach, VA 23454, US

HSTC Financials

Key Financial Metrics (TTM)

Gross Margin

79.41%

Operating Margin

-45.88%

Net Income Margin

-57.64%

Return on Equity

-3.64%

Return on Capital

-6.09%

Return on Assets

-3.33%

Earnings Yield

-0.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$91.93M

Shares Outstanding

141.43M

Volume

Avg. Volume

61.032

Financials (TTM)

Gross Profit

$609.86K

Operating Income

-$352.31K

EBITDA

-$194.22K

Operating Cash Flow

-$1.49M

Capital Expenditure

-$11.00

Free Cash Flow

-$1.49M

Cash & ST Invst.

$20.62K

Total Debt

$928.68K

Hst Global Performance Analysis

Hst Global annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 523,980	N/A

Hst Global sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	108.4%
Q1	2026-03-31	-44.0%
Q2	2026-06-30	33.6%

Hst Global annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.03	-2.5%
2023	2023-12-31	USD -0.03	1.1%
2024	2024-12-31	USD -0.00	-84.2%
2025	2025-12-31	USD -0.01	38.6%

Hst Global sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	14.8%
Q4	2025-12-31	43.5%
Q1	2026-03-31	100.0%
Q2	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$206.06K

N/A

Gross Profit

$165.98K

+514.1%

Gross Margin

80.55%

N/A

Market Cap

$91.93M

N/A

Market Cap/Employee

$91.93M

N/A

Employees

N/A

Net Income

$5.64K

+103.6%

EBITDA

$83.58K

+182.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$20.62K

+704.1%

Total Debt

$928.68K

-18.6%

Accounts Receivable

$251.43K

+5880.8%

Inventory

$393.36K

N/A

Long Term Debt

$211.32K

-58.1%

Short Term Debt

$717.36K

+12.8%

Return on Assets

-3.33%

N/A

Return on Invested Capital

-2.83%

N/A

Free Cash Flow

-$33.92K

+59.2%

Operating Cash Flow

-$33.92K

+59.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ONPHOncology Pharma Inc.

ONPHOncology Pharma Inc.$0.05+0.00%

INFIQInfinity Pharmaceuticals, Inc.

INFIQInfinity Pharmaceuticals, Inc.$0.00+0.00%

GSRXGSRX Industries Inc.

GSRXGSRX Industries Inc.$0.00+0.00%

BTAXBiostax Corp.

BTAXBiostax Corp.$0.00+0.00%

STABStatera Biopharma, Inc.

STABStatera Biopharma, Inc.$0.00+0.00%

LIFSLife Stem Genetics Inc.

LIFSLife Stem Genetics Inc.$0.00+0.00%

ARDSAridis Pharmaceuticals, Inc.

ARDSAridis Pharmaceuticals, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$9.83+0.06%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$41.21+0.06%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$131.46-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.73-0.05%

MRNAModerna

MRNAModerna$134.00-0.23%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$17.69+0.11%

WMTWalmart

WMTWalmart$104.12-0.09%

Questions About HSTC

What is the current price of Hst Global?

Hst Global is trading at $0.65 per share.

What is the 52-week range for Hst Global?

Over the past 52 weeks, Hst Global has traded between $0.00 and $1.05.

How much debt does Hst Global have?

As of the most recent reporting period, Hst Global reported total debt of $928.68K.

How much cash does Hst Global have on hand?

Hst Global reported $20.62K in cash and cash equivalents in its most recent financial results.

What is Hst Global’s dividend yield?

Hst Global does not currently have a dividend yield.

Hst Global(OTC) HSTC

Hst Global Financials at a Glance

HSTC News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Hst Global

HSTC Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Hst Global Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HSTC

What is the current price of Hst Global?

What is the 52-week range for Hst Global?

How much debt does Hst Global have?

How much cash does Hst Global have on hand?

What is Hst Global’s dividend yield?

Premium Investing Services